AbbVie's new arthritis drug, Rinvoq, has proven superior to its predecessor, Humira, signaling a major shift in the immunology market. This theme focuses on the innovative pharmaceutical companies poised to benefit from the demand for more effective autoimmune disease treatments.
Published on October 21
AbbVie's Rinvoq has proven significantly more effective than the former world's best-selling drug, Humira. This validates the potential for next-generation treatments to redefine standards of care across the entire immunology sector.
As legacy autoimmune drugs face patent expirations, innovative companies are positioned to capture substantial market share with superior therapies. The proven success of newer treatments creates powerful momentum for the entire sector.
This collection offers tactical exposure to one of healthcare's most promising areas, where intensive R&D is creating novel oral and injectable therapies. Both established leaders and clinical-stage biotechs represent significant growth potential.
Recent clinical trials have shown that newer autoimmune treatments can significantly outperform established blockbuster drugs. This creates a powerful shift in the immunology market, where next-generation therapies are proving superior in efficacy and safety. We've identified companies positioned to benefit from this transition toward more effective treatments for autoimmune diseases.
This group focuses on biopharmaceutical companies developing innovative oral and injectable therapies for autoimmune conditions. Many legacy drugs are facing patent expirations, creating opportunities for disruptive treatments. The companies range from established leaders successfully navigating this transition to clinical-stage biotechs with promising pipelines in this high-growth healthcare sector.
These companies were handpicked by professional analysts based on their potential to capture substantial market share in the evolving immunology space. The selection includes both proven innovators and emerging biotechs positioned to challenge established standards of care. Each represents tactical exposure to the ongoing shift toward next-generation autoimmune treatments.
Interpretation of basket market capitalisation and investor takeaways for 'The New Guard In Autoimmune Treatment' basket.
ABBV: $409.95B
VRTX: $107.45B
AUPH: $1.56B
Get the full story on this Basket. Read our detailed article on its risks and potential.
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Part of Exinity Group 2015, serving over a million customers globally.
Earn 6% AER on uninvested cash with daily interest payments.
Disney is suing the FCC to block an early license review of its ABC stations, arguing the move is politically motivated retaliation against its news coverage. This unprecedented legal battle highlights the growing regulatory risks for traditional broadcasters and underscores the structural advantages of unregulated digital streaming platforms.
SK Hynix has unveiled a record-breaking 40 trillion won share buyback fueled by soaring demand for its AI memory chips. This historic capital return creates a compelling investment theme centered on high-bandwidth memory producers and the specialized equipment manufacturers that enable their advanced production.
Home Depot's recent earnings beat highlights consistent consumer spending on smaller household repair and maintenance projects. This ongoing trend presents promising opportunities for various home improvement retailers and building material suppliers.
+6
Here are a few of the assets in this group. Create an account to unlock the full list.
Use the growth calculator to see how much investing in these assets could return over one year, based on aggregated analyst sentiment provided by Refinitive Ltd.
If you invested across these assets:
In 12 months it might be worth:
+150.89%
On average, analysts expect assets in this group to grow 150.89% over the next year.
13 of 13 assets in this group are rated Buy by professional analysts.
